Literature DB >> 9740535

The role of lipid-lowering therapy in multiple risk factor management.

R J Esper1.   

Abstract

Epidemiological studies have demonstrated that the risk of death from coronary heart disease (CHD) increases in parallel with increasing serum cholesterol levels. The risk is highest in patients with severely elevated cholesterol levels [i.e. > 6.2 mmol/L(240 mg/dl)]. However, even in patients with serum cholesterol levels of 4.7 to 5.7 mmol/L (180 to 220 mg/dl), mortality from CHD is 30 to 70% higher than in patients with cholesterol levels < 4.7 mmol/L (180 mg/dl). A number of factors other than serum total cholesterol levels affect CHD risk. It is increasingly accepted that dysfunction of the vascular endothelium contributes to the pathogenesis of atherosclerosis. Experimental evidence and clinical studies suggest that endothelium-derived nitric oxide (NO) plays an important role as an endogenous antiatherogenic molecule, and that reduced levels of NO may promote progression of atherosclerosis. Hypercholesterolaemia can hasten atherogenesis in part by reducing levels of NO. In humans, it is possible to evaluate the effects of hypercholesterolaemia by measuring the vasodilator response to pharmacological or physical stimuli that increase the synthesis and release of endothelium-derived NO. The use of high resolution external ultrasound to assess post-ischaemic brachial artery vasodilation in patients with cardiovascular risk factors has demonstrated that endothelial dysfunction exists, even in the absence of overt atherosclerotic plaques. Impaired endothelium-dependent vasodilation has been observed in asymptomatic individuals with hypercholesterolaemia, as well as in patients with other recognised risk factors. Dietary and pharmacological lipid lowering has been shown to produce improvements in endothelial-dependent vasodilation. Among normocholesterolaemic healthy young individuals without cardiac risk factors, endothelium-dependent vasodilation was more likely to be impaired in those with relatively higher total and low density lipoprotein-cholesterol levels (i.e. above versus below the 25th percentile). This suggests that an inverse and continuous relationship exists between the prevailing cholesterol level and endothelial function. The implication of these findings is that the treatment of hypercholesterolaemia remains, at present, an underutilised means of reducing CHD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9740535     DOI: 10.2165/00003495-199856001-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  43 in total

1.  Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

Authors:  M A Austin; M C King; K M Vranizan; R M Krauss
Journal:  Circulation       Date:  1990-08       Impact factor: 29.690

Review 2.  The endothelium in coronary artery disease.

Authors:  F T Ruschitzka; G Noll; T F Lüscher
Journal:  Cardiology       Date:  1997       Impact factor: 1.869

3.  Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.

Authors:  M J Martin; S B Hulley; W S Browner; L H Kuller; D Wentworth
Journal:  Lancet       Date:  1986-10-25       Impact factor: 79.321

4.  Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults.

Authors:  P Clarkson; M R Adams; A J Powe; A E Donald; R McCredie; J Robinson; S N McCarthy; A Keech; D S Celermajer; J E Deanfield
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

5.  Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor.

Authors:  G M Rubanyi; P M Vanhoutte
Journal:  Am J Physiol       Date:  1986-05

6.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

7.  Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery endothelium.

Authors:  A M Lefer; X L Ma
Journal:  Arterioscler Thromb       Date:  1993-06

8.  Low-density lipoprotein subclass patterns and risk of myocardial infarction.

Authors:  M A Austin; J L Breslow; C H Hennekens; J E Buring; W C Willett; R M Krauss
Journal:  JAMA       Date:  1988-10-07       Impact factor: 56.272

9.  The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.

Authors:  T J Anderson; I T Meredith; A C Yeung; B Frei; A P Selwyn; P Ganz
Journal:  N Engl J Med       Date:  1995-02-23       Impact factor: 91.245

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  3 in total

Review 1.  Current, new and future treatments in dyslipidaemia and atherosclerosis.

Authors:  P H Chong; B S Bachenheimer
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 2.  Advances in diabetes for the millennium: diabetes and cholesterol.

Authors:  Marc Rendell
Journal:  MedGenMed       Date:  2004-10-06

Review 3.  Endothelial dysfunction: a comprehensive appraisal.

Authors:  Ricardo J Esper; Roberto A Nordaby; Jorge O Vilariño; Antonio Paragano; José L Cacharrón; Rogelio A Machado
Journal:  Cardiovasc Diabetol       Date:  2006-02-23       Impact factor: 9.951

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.